191 related articles for article (PubMed ID: 37520059)
1. Treatment of immunoglobulin-resistant kawasaki disease: a Bayesian network meta-analysis of different regimens.
Pan Y; Fan Q; Hu L
Front Pediatr; 2023; 11():1149519. PubMed ID: 37520059
[TBL] [Abstract][Full Text] [Related]
2. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
3. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
4. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
5. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
Wang L; He M; Wang W; Li S; Zhao G
Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
[TBL] [Abstract][Full Text] [Related]
8. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
10. Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy.
Miura M; Tamame T; Naganuma T; Chinen S; Matsuoka M; Ohki H
Paediatr Child Health; 2011 Oct; 16(8):479-84. PubMed ID: 23024586
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
[TBL] [Abstract][Full Text] [Related]
12. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
13. Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea.
Hur G; Song MS; Sohn S; Lee HD; Kim GB; Cho HJ; Yoon KL; Joo CU; Hyun MC; Kim CH
Korean Circ J; 2019 Feb; 49(2):183-191. PubMed ID: 30468032
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M
Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of infliximab for Kawasaki disease in children: systematic review and meta-analysis.
Li D; Li X; Dou W; Zheng Y
Transl Pediatr; 2021 May; 10(5):1294-1306. PubMed ID: 34189087
[TBL] [Abstract][Full Text] [Related]
16. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
17. [Methylprednisolone pulse therapy in Kawasaki disease].
Miura M; Matsuoka M; Kohno K; Ohki H; Yoshiba S
Nihon Rinsho; 2008 Feb; 66(2):338-42. PubMed ID: 18265457
[TBL] [Abstract][Full Text] [Related]
18. TNF-α blockers for the treatment of Kawasaki disease in children.
Yamaji N; da Silva Lopes K; Shoda T; Ishitsuka K; Kobayashi T; Ota E; Mori R
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012448. PubMed ID: 31425625
[TBL] [Abstract][Full Text] [Related]
19. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
20. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
Dionne A; Burns JC; Dahdah N; Tremoulet AH; Gauvreau K; de Ferranti SD; Baker AL; Son MB; Gould P; Fournier A; Newburger JW; Friedman KG
Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]